Clarivate (CLVT) Q2 2025 Earnings Call July 30, 2025 09:00 AM ET Company ParticipantsMark Donohue - VP - Investor RelationsMatti Shem Tov - CEO & DirectorJonathan Collins - EVP & CFOOwen Lau - Executive DirectorWilliam Qi - Equity Research Senior AssociateAdam Parrington - AVPConference Call ParticipantsManav Patnaik - MD & Equity Research AnalystToni Kaplan - Executive Director & Lead Analyst - Equity ResearchGeorge Tong - Senior Research Analyst - Equity Research & Business ServicesOperatoryou for standin ...

Clarivate (CLVT) Q2 2025 Earnings Call July 30, 2025 09:00 AM ET Speaker0you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Clarivate Second Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.Thank you. I would now like to turn the call over to Mark Donahue, Vice President of Investor ...

Q2 2025 Earnings Call July 30, 2025 Safe Harbor Statement and Non-GAAP Financial Measures Forward-Looking Statements This communication includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _______ Commission File No. 001-38911 CLARIVATE PLC (Exact name of registrant as specified in its charter) Jersey, Channel Islands Not applicable (State or othe ...

Net loss for the second quarter of 2025 was $72.0 million, or $0.11 per diluted share, compared to a net loss of $304.3 million, or $0.46 per diluted share, for the second quarter of 2024. Adjusted net income for the second quarter of 2025 was $123.3 million, or $0.18 per diluted share, compared to $142.2 million, or $0.20 per diluted share, for the second quarter of 2024. Adjusted EBITDA for the second quarter of 2025 was $261.6 million, compared to Adjusted EBITDA of $274.4 million for the second quarter ...

LONDON, July 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that Maroun S. Mourad will join the Company as President of the Intellectual Property (IP) segment, effective September 8, 2025. Maroun most recently served as President of the Claims Solutions division of Verisk Analytics Inc. He succeeds Gordon Samson, who will retire at the end of 2025 after a high-impact career in the IP industry, spending five years as the Chief Ope ...

Core Insights - The 2025 G20 research and innovation scorecard by Clarivate highlights the evolving research strategies of G20 nations, emphasizing open access, international partnerships, and alignment with global challenges like the Sustainable Development Goals (SDGs) [5][6] - The scorecard incorporates data from the Emerging Sources Citation Index (ESCI), enhancing its ability to reflect global research activity [2] - The scorecard is available for free on Clarivate's website and is launched ahead of the G20 Summit in Johannesburg, South Africa [4] Research Collaboration Trends - The European Union's collaboration with Mainland China has more than doubled from 3.0% in 2015 to 6.6% in 2024, while partnerships with the U.S. and U.K. remain steady at 12% and 9% respectively [8] - Mainland China leads the G20 in research output with nearly 900,000 papers in 2024, tripling its 2015 volume, with over half involving domestic collaboration [8] - The United States has seen international collaboration increase to 43%, with Mainland China being its largest international partner [8] - The United Kingdom's international collaboration has grown from 55% in 2015 to 70% in 2024, with significant increases in partnerships with Mainland China [8] - Canada maintains strong ties with the U.S., with 26.8% of Canadian papers co-authored with U.S. researchers, primarily in Medical & Health Sciences [8] - Australia has seen Mainland China overtake the U.S. as its top research partner, with collaboration rising from 9.7% in 2015 to 19.5% in 2024 [8] Scorecard Features - The scorecard includes OECD field-level breakdowns and insights into open access and SDG-aligned research, reflecting G20 host South Africa's Ubuntu philosophy of collaboration [3] - Enhanced visualizations and field-level insights are designed to make it easier to explore trends and understand the dynamics shaping global science [6]

Financial Results Announcement - Clarivate Plc will report its financial results for the second quarter of 2025 before the market opens on July 30, 2025 [1] - The press release and earnings supplement will be available on the Clarivate investor website [1] Conference Call Details - The company will host a conference call and webcast at 9:00 AM Eastern Time on July 30, 2025, to review the results [2] - The webcast is open to all interested parties and may include forward-looking information [2] Access Information - Interested parties can access the live audio broadcast via specific phone numbers for U.S. and international participants [3] - A replay of the webcast will be available on the investor relations website starting two hours after the live call and will remain accessible for one year [3] Company Overview - Clarivate is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services in various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [4]

Core Insights - Clarivate Plc has released the 2025 update to the Journal Citation Reports (JCR), marking the 50th anniversary of these influential annual reports that assess the trustworthiness and impact of academic journals [1][3] Company Overview - Clarivate is recognized as a leading global provider of transformative intelligence, offering enriched data, insights, analytics, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [6] JCR Highlights - The 2025 JCR includes data from 22,249 journals across 254 categories, with over 6,200 published via gold open access [6] - Scholarly journals from 111 countries are acknowledged, with 14,591 in the sciences, 7,559 in social sciences, and 3,368 in arts and humanities [6] - This year, 618 journals received a Journal Impact Factor (JIF) for the first time [6] - The calculation of JIF now excludes citations to and from retracted content, ensuring that such citations do not affect the JIF numerator, although retracted articles remain in the article count for transparency [6]

Core Insights - The report by Clarivate Plc highlights emerging companies in the field of radioligand therapies (RLTs) that are transforming cancer care through precision oncology innovations [1][3] - RLTs are gaining traction as a promising approach in oncology, delivering radioactive isotopes directly to tumor cells while minimizing harm to healthy tissues [2][3] Company Highlights - **Affibody**: A clinical-stage biopharmaceutical company focused on oncology and immunology, utilizing its proprietary Affibody® technology platform to develop next-generation biopharmaceutical drugs [4] - **Alpha-9 Oncology**: Developing targeted radiopharmaceuticals for various malignancies, leveraging expertise in peptide and small molecule modifications [4] - **Ariceum Therapeutics**: Focused on radiopharmaceutical theranostic pairs for aggressive tumors, with its lead product satoreotide targeting somatostatin receptor 2 [4] - **Convergent Therapeutics**: Developing radioantibodies for cancer treatment, with its lead candidate in phase 2 trials for metastatic castration-resistant prostate cancer [5] - **Perspective Therapeutics**: Employing a theranostic approach with proprietary chelator technology for radiolabeling targeting moieties against cancers [9] - **PRECIRIX®**: Developing radiopharmaceutical theranostics using camelid single-domain antibodies against multiple targets, focusing on FAP-positive tumors [9] Market Trends - The global radiopharmaceutical market is projected to exceed $13 billion within the next decade, indicating significant growth potential for companies in this sector [7] - Notable acquisitions in the RLT field include Bristol Myers Squibb's $4.1 billion acquisition of RayzeBio and AstraZeneca's $2.4 billion acquisition of Fusion Pharmaceuticals, reflecting strategic investments in this area [6] Research and Development Insights - The report provides a comprehensive overview of the RLT landscape, including scientific advancements, clinical potential, and market dynamics [3] - It emphasizes the importance of differentiated R&D strategies and intellectual property positioning in setting companies apart in the competitive landscape [3][8]